When the type is not documented, default to Type 2 (E11) per guideline
This guide deliberately reports mechanisms as mechanisms
Understanding how the microbiome is involved in establishing, maintaining, and reversing obesity has been an active area of research 14,15,16 , and has included studies investigating links between the microbiome and obesity-related comorbidities such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) 17,18
Tesofensine at doses of 0.5 mg and 1.0 mg increased heart rate by 7.4 and 8.1 beats per min, respectively [76]
Rat medial collateral ligament transection models demonstrated that BPC-157 restored biomechanical properties including load capacity, stiffness, and breaking force to near-normal levels
Efficacy and safety of LY3298176 (Tirzepatide), a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (Phase 2 trial)